Zobrazeno 1 - 10
of 68
pro vyhledávání: '"35"'
Autor:
N Rueth, Karen K. Swenson, M Knaack, Janet Krueger, Barbara Susnik, P Martone, SR Baldinger, Michaela Tsai, Erin Grimm, Tamera J. Lillemoe
Publikováno v:
Cancer Research. 79:P5-10
Background: While breast cancer is rare in women ≤ age 35, patients in this age group are more frequently diagnosed with aggressive cancer subtypes and pathologic germline mutations in cancer susceptibility genes than older patients. Higher recurre
Autor:
Patricia A. Thompson, Michelle Turner, Carolyn Mies, Jules Cohen, Caterina Vacchi-Suzzi, Alison Stopeck, Lea N. Baer, Christina Preece, Christy A. Russell, Rebecca Batiste, Julie Anne L Gemmill
Publikováno v:
Cancer Research. 81:PS5-37
Background: Identifying when to start CDK4/6 inhibitors or use chemotherapy in hormone receptor positive (HR+) metastatic breast cancer (MBC) remains challenging. The 21-gene Oncotype DX Breast Recurrence Score® test is validated to predict chemothe
Autor:
Fanny Leenhardt, Bénédicte Marion, Claudia Muracciole-Bich, Stéphane Pouderoux, Alexandre Evrard, Catherine Perrin, Céline Roques, Litaty Mbatchi, Marie Alexandre, William Jacot, Céline Gongora, Matthieu Gracia, Nelly Firmin
Publikováno v:
Cancer Research. 81:PS5-16
Background: The CDK4/6 inhibitors palbociclib is prescribed in association with hormonal therapy for the management of metastatic breast cancer patients. Like most oral targeted drug, therapeutic drug monitoring may be used for personalize their dosa
Publikováno v:
Cancer Research. 81:PD11-07
Background. High mammographic density decreases sensitivity of both 2D and 3D mammography. Tamoxifen reduces mammographic density thereby potentially increasing screening sensitivity. We tested if low-dose tamoxifen could be used to increase sensitiv
Publikováno v:
Cancer Research. 81:2771-2771
In recent years, novel immunotherapy strategies have shown remarkable results in treating various advanced cancers. The efficacy of immunotherapeutics has been dictated by the dynamic and spatially heterogeneous tumor microenvironment (TME) which inc
Autor:
Nancy Tray, Karen Hiotis, Deborah Axelrod, Victor Ty, Judith D. Goldberg, Farbod Darvishian, Maryann Kwa, Yelena Novik, Sylvia Adams, Amber A. Guth, James L. Speyer, Adriana Heguy, Douglas K. Marks
Publikováno v:
Cancer Research. 80:OT1-01
BACKGROUND: Receptor activator of NF-kB (RANK) and its ligand (RANKL) have a well-established role in osteoclast-driven bone remodeling, however RANK/RANKL expression can also be seen on mammary epithelial cells and immune cells (IC). In breast cance
Publikováno v:
Cancer Research. 79:3316-3316
Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition syndrome, caused primarily by germline pathogenic TP53 variants and associated with a very high lifetime cancer risk which reaches approximately 100% by age 60 years. Individua
Autor:
Masakazu Toi, Zhipeng Wang, Kazuharu Shimizu, Norikazu Masuda, Takayuki Ueno, Yoshiki Mikami, Fumiaki Sato, Akira Myomoto, Satoko Takizawa, Gozoh Tsujimoto
Publikováno v:
Cancer Research. 72:P5-10
[Background and Aim] Although Trastuzumab has been used for HER2(+) breast cancer, the treatment response of Trastuzumab therapy depends on unknown mechanisms among individual cases. In order to avoid unnecessary adverse events and to lighten financi
Autor:
Min-Hsien Wu, Siou-Ru Ye, Hung-Ming Wang, Ting-Hsiuan Yeh, Jason Chia-Hsun Hsieh, Jane Ying-Chieh Lee, Yung-Chang Lin, Nina Ming-Jung Lin
Publikováno v:
Cancer Research. 77:3790-3790
Background: Circulating tumor cell (CTC) has been prognostic and predictive in numerous types of cancer; however, its role in early diagnosis of relapse remains unclear. Methods: Eighty-six patients were prospectively enrolled between March 2015 and
Autor:
Charles E. Cox, Shiyu Wang, Lisa Blumencranz, Amy Truitt, Andrea Menicucci, Steven C. Shivers, Mehran Habibi, Peter W. Blumencranz, William Audeh, Jolanta L. Baginski, Geza Acs
Publikováno v:
Cancer Research. 81:PS6-41
Background: Elderly breast cancer (BC) patients are an understudied population, with limited evidence regarding treatment options and outcomes and a lack of research involving prognostic multigene assays for this group. One study in patients 65-89 ye